Clik here to view.
Noxopharm Achieves Abscopal Responses in Prostate Cancer
SYDNEY Noxopharm, a clinical-stage Australian oncology drug development company, has announced the details of the radiographic review of its DARRT-1 clinical study and is pleased to report a 27%...
View ArticleClik here to view.
Daiichi Sankyo Submits Supplemental New Drug Application for Trastuzumab...
TOKYO & MUNICH & BASKING RIDGE, N.J. Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has submitted a supplemental New Drug Application (sNDA) to Japan’s...
View ArticleClik here to view.
CANbridge Pharmaceuticals Receives Marketing Approval for NERLYNX®...
BEIJING & SHANGHAI CANbridge Pharmaceuticals Inc., a biopharmaceutical company developing innovative drug candidates to treat underserved medical conditions in China and other markets, announced...
View ArticleClik here to view.
ENHERTU® Granted Breakthrough Therapy Designation in the U.S. for HER2...
TOKYO, BASKING RIDGE, N.J. & MUNICH Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been granted Breakthrough Therapy...
View ArticleClik here to view.
Frazier Healthcare Partners Launches Lengo Therapeutics
MENLO PARK, Calif. & BANGALORE, India Frazier Healthcare Partners (“Frazier”) today announced the launch of Lengo Therapeutics, Inc. (“Lengo”), a biopharmaceutical company focused on the...
View ArticleClik here to view.
Legend Biotech and Noile-Immune Biotech Announce Collaborative Research and...
SOMERSET, N.J., USA and TOKYO, Japan Legend Biotech Corporation (“Legend”), a global clinical stage biopharmaceutical company engaged in the discovery and development of novel cell therapies,...
View ArticleClik here to view.
Modulus Discovery Closes $25.5M USD Series B
TOKYO Modulus Discovery, Inc., a preclinical-stage technology-driven drug discovery firm, announces the successful closing of its series B funding round in the amount of 2.71 B JPY (approximately...
View ArticleClik here to view.
China NMPA Approves Optune® for the Treatment of Newly Diagnosed and...
ST. HELIER, Jersey & SHANGHAI Novocure (NASDAQ: NVCR), a global oncology company with a proprietary platform therapy called Tumor Treating Fields, and Zai Lab Limited (NASDAQ: ZLAB), an...
View ArticleClik here to view.
European Commission Approves ADCETRIS® (brentuximab vedotin) for Treatment of...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the European Commission (EC) extended the current conditional marketing...
View ArticleClik here to view.
Takeda to Present Data at Upcoming Virtual Scientific Congresses,...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) (“Takeda”) today announced that the company will present data from its expanding oncology pipeline and...
View ArticleClik here to view.
Samsung Bioepis Announces Four-year Follow-up Data for Biosimilar ONTRUZANT®...
INCHEON, Korea Samsung Bioepis Co., Ltd. announced today that four-year follow-up results of the Phase 3 study for ONTRUZANT®, a biosimilar of the reference medicine HERCEPTIN®1 (trastuzumab), will...
View ArticleClik here to view.
LegoChem Biosciences and Iksuda Enter Licensing Agreement for Antibody Drug...
DAEJEON, South Korea LegoChem Biosciences, Inc. (“LCB”) (KOSDAQ:141080), based in Daejeon, South Korea, announced today a worldwide license agreement with Iksuda Therapeutics (“Iksuda”) for the...
View ArticleClik here to view.
ENHERTU® Granted Breakthrough Therapy Designation in the U.S. for HER2 Mutant...
TOKYO & BASKING RIDGE, N.J. & MUNICH Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been granted Breakthrough...
View ArticleClik here to view.
欧盟委员会核准ADCETRIS® (brentuximab vedotin)用于治疗既往未曾治疗的全身性间变性大细胞淋巴瘤成人患者
马萨诸塞州剑桥和日本大阪 (美国商业资讯)–武田药品工业株式会社(Takeda Pharmaceutical Company Limited, TSE:4502/NYSE:TAK)（“武田”）今天宣布，欧盟委员会(EC)扩大了ADCETRIS® (brentuximab...
View ArticleClik here to view.
武田薬品が来るバーチャル学会で当社の幅広いオンコロジーポートフォリオと新たなパイプラインを浮き彫りにするデータを発表へ
米マサチューセッツ州ケンブリッジ & 大阪 （ビジネスワイヤ） — 武田薬品工業株式会社（TSE:...
View ArticleClik here to view.
欧州委員会が未治療の全身性未分化大細胞リンパ腫成人患者の治療薬としてアドセトリス（ブレンツキシマブ・ベドチン）を承認
米マサチューセッツ州ケンブリッジ & 大阪 （ビジネスワイヤ） —...
View ArticleClik here to view.
武田将在即将召开的虚拟科学大会上呈报数据，强调肿瘤产品阵容和后续产品管线的广度
马萨诸塞州剑桥和日本大阪 (美国商业资讯)–武田药品工业株式会社(Takeda Pharmaceutical Company Limited) (TSE: 4502/NYSE:TAK)...
View ArticleClik here to view.
Rising Pharmaceuticals to Support Phase 2 Clinical Trial of Chloroquine...
EAST BRUNSWICK N.J. Rising Pharma Holdings Inc., the pharmaceutical company now operating as Rising Pharmaceuticals, today announced the support of a Phase 2 clinical trial designed to determine the...
View ArticleClik here to view.
Genetron Health Announces Strategic Collaboration with DARUI on GENETRON S5...
BEIJING Genetron Holdings Limited (“Genetron Health”), a China-based precision oncology company that covers full-cycle cancer care, announced that it has joined forces with DARUI. The partnership...
View ArticleClik here to view.
ENHERTU® Granted Orphan Drug Designation in the U.S. for Gastric Cancer
TOKYO & BASKING RIDGE, N.J. Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been granted Orphan Drug Designation...
View Article